Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;36(1):26-36.
doi: 10.1007/s12288-019-01170-1. Epub 2019 Sep 16.

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Zahra Moradi  1 , Amirhosein Maali  2   3 , Javad Sadeghi Shad  2   4 , Alireza Farasat  5 , Reza Kouchaki  6 , Mona Moghadami  2   3 , Mohamad Hosein Ahmadi  6 , Mehdi Azad  6
Affiliations
Review

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Zahra Moradi et al. Indian J Hematol Blood Transfus. 2020 Jan.

Abstract

Erythropoietin (EPO) is an important hormone responsible for the stimulation of hematopoiesis which is impaired in a variety of diseases, such as chronic kidney disease, cancer chemotherapy, and the use of some anti-HIV drugs. Difficulties in the purification of endogenous EPO due to problems such as technical limitations, heterogeneity of target cells, inadequate amount and immunogenicity of the resultant product, had limited the entry of endogenous EPO in the clinical applications. The integration of medical biotechnology and hematology has introduced novel procedures for the production of human recombinant erythropoietin (rHuEPO), and other erythropoiesis-stimulating agents (ESAs). To investigate and produce rHuEPO, the first step is to recognize the molecular biology and functional pathways, structure, metabolism, and basic physiology of EPO. In this review, all clinical indications, side effects, challenges and notable points regarding EPO, rHuEPO, and other ESAs have also been addressed along with its molecular characterization, such as the modifications needed to optimize their rHuEPO biosynthesis.

Keywords: Erythropoiesis-stimulating agents; Erythropoietin; Human recombinant erythropoietin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that there is no conflict of interests.

Figures

Fig. 1
Fig. 1
Biological structure of EPO. Erythropoietin has two intramolecular di-sulfide bonds at positions Cys7–Cys161 and Cys29–Cys33. Moreover, the N-glycosylated bonds at the asparagine 24, 38, and 83 residues and an O-glycosidic bond is located at amino acid position 126
See this image and copyright information in PMC

References

    1. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21(4):414–421. - PubMed
    1. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem. 1986;261(7):3116–3121. - PubMed
    1. Tran AD, Park S, Lisi PJ, Huynh OT, Ryall RR, Lane PA. Separation of carbohydrate-mediated microheterogeneity of recombinant human erythropoietin by free solution capillary electrophoresis. Effects of pH, buffer type and organic additives. J Chromatogr. 1991;542(2):459–471. - PubMed
    1. European Medicines Agency. Silapo: EPAR summary for the public 2007. http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en1.pdf. 4 Mar 2008
    1. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins. 1992;12(4):345–364. - PubMed

LinkOut - more resources